Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Hogan

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|November 27, 2010
Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapyCharles Wayne Weart, Richard J Hogan
Microbes and Infection|November 5, 2005
Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infectionsAdam Polkinghorne, Richard J Hogan, Lloyd Vaughan, et al.
Infection and Immunity|March 25, 2004
Chlamydial persistence: beyond the biphasic paradigmRichard J Hogan, Sarah A Mathews, Sanghamitra Mukhopadhyay, et al.
Microbial Pathogenesis|March 7, 2003
Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infectionsRichard J Hogan, Sarah A Mathews, Andrei Kutlin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 31, 2019
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapyEva Havrdova, Douglas L Arnold, Jeffrey A Cohen, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|November 27, 2010
Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapyCharles Wayne Weart, Richard J Hogan
Microbes and Infection|November 5, 2005
Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infectionsAdam Polkinghorne, Richard J Hogan, Lloyd Vaughan, et al.
Infection and Immunity|March 25, 2004
Chlamydial persistence: beyond the biphasic paradigmRichard J Hogan, Sarah A Mathews, Sanghamitra Mukhopadhyay, et al.
Microbial Pathogenesis|March 7, 2003
Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infectionsRichard J Hogan, Sarah A Mathews, Andrei Kutlin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 31, 2019
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapyEva Havrdova, Douglas L Arnold, Jeffrey A Cohen, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Pageof 1